Psoriatic arthritis plus obesity is not only a weight conversation. The trial review separates ACR20 and ACR50 joint response from a composite endpoint driven partly by weight loss, and reminds clinicians to counsel gastrointestinal adverse effects before adding tirzepatide.

New myositis drugs are easy to overread from the headline result alone. This review separates skin response, muscle response, steroid sparing, infection risk, and the unanswered question of where brepocitinib sits beside IVIG and conventional DMARDs.